Skip to main content
. 2020 Sep 23;123(12):1720–1729. doi: 10.1038/s41416-020-01074-2

Fig. 4. In vitro experiments for cell proliferation in the PDX models showing synergy of buparlisib/cetuximab.

Fig. 4

a Comparison of gene expression profiles between buparlisib, cetuximab, buparlisib/cetuximab and control in PDX models YHIM-05, -06 and -07, showing that genes associated with apoptosis and cell-cycle arrest were significantly upregulated by combination therapy. b Cell viability as a function of drug treatment of cell lines from PDX models YUX-06 and -07). c Expression of genes related to cell-cycle progression (cyclins B, D and E) and apoptosis (cleaved PARP, cleaved caspase-3 and cleaved-7) in YUX-06 and -07. d IHC showing proliferative (Ki67) and apoptotic (TUNEL) markers in YHIM-06 and -07. e Flow cytometry showing apoptosis in YUX-06 and -07.